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Abstract
Background: Thiazolidinediones, used for the treatment of patients with type 2 diabetes mellitus (DM2), are
associated with an increased incidence of heart failure. We sought to investigate the effects of pioglitazone on
novel echocardiographic indices of left ventricular (LV) diastolic function in DM2 patients with LV diastolic
dysfunction (LVDD).
Methods: Eighty-eight asymptomatic DM2 patients on metformin and/or sulfonylureas, aged 64.5 ± 7.7 years,
without known cardiovascular disease, with normal LV systolic function and evidence of LVDD were randomly
assigned to pioglitazone 30 mg/day (n = 42) or an increase in dose of other oral agents (n = 39) for 6 months. All
patients underwent transthoracic conventional and Tissue Doppler Imaging echocardiography at baseline and
follow-up. The primary end-point was change in early diastolic velocity of the mitral annulus (E’).
Results: Improvement of glycaemic control was similar in the 2 groups. A significant difference (p < 0.05) between
the 2 groups was found in the treatment-induced changes in fasting insulin, the insulin resistance index HOMA,
HDL cholesterol, triglycerides, diastolic blood pressure (all in favor of pioglitazone) and in body weight (increase
with pioglitazone). No significant changes were observed in any echocardiographic parameter in either group and
did not differ between groups (p = NS for all). E’ increased non-significantly and to a similar extent in both groups
(p = NS).
Conclusions: In asymptomatic DM2 patients with LVDD, the addition of pioglitazone to oral conventional
treatment for 6 months does not induce any adverse or favorable changes in LV diastolic or systolic function
despite improvements in glycaemic control, insulin sensitivity, lipid profile, and blood pressure.
Background
Diabetes mellitus (DM) is associated with a substantially
increased risk of developing heart failure (HF) [1].
Although the association between diabetes and HF has
been well established, the underlying mechanisms
remain vague. Co-existing morbidities, such as hyperten-
sion, microangiopathy, myocardial ischemia and renal
dysfunction may explain the development of HF in type
2 DM (DM2) patients. The existence of ‘diabetic cardio-
myopathy’, a distinct clinical process leading to HF in
diabetic patients regardless of the presence of athero-
sclerosis and hypertension has also been suggested [2,3].
Left ventricular (LV) diastolic dysfunction (LVDD) has
been recognized as an early manifestation of myocardial
dysfunction in DM2 patients; LVDD assessed by echo-
cardiography has been demonstrated in up to 60-75% of
asymptomatic DM2 patients [4,5].
* Correspondence: lmihalis@cc.uoi.gr
1Michaelidion Cardiac Center, University of Ioannina, University Campus,
Ioannina, 45 110 Greece
Full list of author information is available at the end of the article
Naka et al. Cardiovascular Diabetology 2010, 9:57
http://www.cardiab.com/content/9/1/57
CARDIO
VASCULAR 
DIABETOLOGY
© 2010 Naka et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.Pioglitazone is a thiazolidinedione used for the treat-
ment of DM2 and acts as an insulin sensitizer [6]. Pio-
glitazone has also been shown to improve lipid profile,
blood pressure, inflammatory biomarkers and endothe-
lial function [7], and data suggests that it may reduce
cardiovascular events in DM2 patients [8,9]. However,
pioglitazone administration has been associated with an
increase in the incidence of serious non-fatal HF [9,10],
mainly attributed to weight gain and peripheral edema
[10].
Limited evidence suggests a beneficial effect of piogli-
tazone on LV diastolic function in hypertensive or DM2
patients with normal cardiac function using conven-
tional echocardiography or MRI [11,12], while pioglita-
zone has also been shown to prevent or improve LVDD
in animal studies [13,14]. On the other hand, clinical
studies have demonstrated a neutral effect of pioglita-
zone on cardiac structure and systolic function in DM2
patients with normal [15] or impaired systolic function
[16] using conventional echocardiography. The effects of
pioglitazone on echocardiographic indices in patients
with DM2 and LVDD have not been largely studied,
while Tissue Doppler Imaging (TDI) echocardiography
that allows more direct quantification of LV diastolic
function [17] has been very little used in this context
[18]. In the current study, we investigated the effect of
pioglitazone administration on conventional and TDI
echocardiographic indices of LV function in asympto-
matic DM2 patients with evidence of LVDD.
Methods
Study Population
Eighty-eight DM2 patients on metformin and/or sulfo-
nylurea were enrolled in this study. Inclusion criteria
were: 1) DM2 treated only with metformin and/or sulfo-
nylurea at the time of enrolment, 2) glycaeted haemo-
globin (HbA1C) > 6.5%, 3) evidence of LVDD on
echocardiography with preserved LV ejection fraction
(LVEF > 50%) and absence of any wall motion abnorm-
ality and 4) normal liver enzymes and renal function.
Exclusion criteria were: 1) treatment with pioglitazone
or rosiglitazone or insulin within the previous 6 months,
2) new onset of any medications within the previous 3
months, 3) any history, symptoms, signs of HF, coronary
artery, cerebrovascular, or peripheral vascular disease, 4)
uncontrolled hypertension, 5) atrial fibrillation, 6) more
than mild valvular heart disease, 6) liver or renal disease,
anaemia, thyroid dysfunction or any other major health
problem and 7) diabetes-related complications (prolif-
erative retinopathy and autonomic neuropathy).
Study design
The study was designed as a prospective, randomized,
open- label, blind evaluation with all analyses performed
by personnel unaware of treatment allocation. The study
evaluated echocardiographic indices of LV function in
asymptomatic DM2 patients with evidence of LVDD, on
metformin and/or sulfonylurea treatment, when either
pioglitazone was added to their treatment or ongoing
oral treatment was intensified for 6 months. The pri-
mary end-point was change in early diastolic velocity at
the mitral annulus (E’) from baseline to follow-up. Addi-
tional analyses included changes in glycaemic control,
insulin resistance indices, lipid and blood pressure levels,
LV systolic function indices, Tei index, E/A ratio, diasto-
lic and systolic mitral annular velocities, and E/E’ ratio.
Patients were recruited at the Endocrinology out-patient
clinics of the University and Hatzikosta General Hospi-
tals of Ioannina from October 2004 to April 2006 after
review of their medical history, a complete physical
examination, an electrocardiogram and a transthoracic
echocardiogram. Patients eligible for the study who con-
sented to participate were randomly assigned in a 1:1
ratio using a computer-generated block of 4, into 2
groups. Pioglitazone (30 mg od) was added in group A
(n = 44), while in group B (n = 44) an increase in the
dose of the conventional medication or medications
already received by the patient (metformin and/or sulfo-
nylurea) was prescribed according to the physician’s dis-
cretion in the randomization visit only. Care was taken
so that the type of antidiabetic medications used in this
group remained unchanged during the study (i.e. only
dosage of medications could be increased and no other
medication was added). Group B may be considered as
a substitute for a control group to compare with piogli-
tazone since it was felt unethical to leave DM2 patients
with established myocardial involvement without any
glucose-lowering treatment.
Clinical assessment, blood sampling, and echocardio-
graphic evaluation were performed in all patients at
baseline and 6 months. All other treatment (antihyper-
tensive, hypolipidaemic and antiplatelet) remained unal-
tered during the 6-month study period. Instructions
were given to patients in order to maintain stable diet-
ary habits and physical activity during the study. Liver
enzymes were measured in all patients at 1, 3 and 6
months. The design of the study is presented in a flow-
chart (Figure 1).
The study was approved by the Ethics Committee of
the Michaelidion Cardiac Centre, University of Ioannina,
Greece and written informed consent was obtained from
all patients. The study was conducted in accordance
with the Declaration of Helsinki.
Laboratory investigations
Blood samples were drawn after an overnight fast for
measurement of glucose, insulin, HbA1C, lipid concen-
trations, liver and renal function and full blood count
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using the Friedewald formula: LDL cholesterol = Total
cholesterol - HDL cholesterol - triglycerides/5. The fast-
ing serum glucose was divided by the fasting serum
insulin to calculate the fasting glucose-to-insulin ratio,
an index of insulin sensitivity. The homeostasis model
assessment (HOMA), calculated as (fasting serum glu-
cose [mmol/l] × fasting serum insulin [μU/ml])/22.5,
was used as an index of insulin resistance.
Echocardiography
Echocardiographic studies were performed using an
Echo-Doppler ultrasound unit (Ultrasound ATL, HDI
5000, Bophell, WA, USA) and a 2-3.5 MHz transducer.
Standard 2-dimensional (2D), 2D-guided M-mode, color
flow Doppler and TDI echocardiography was performed
at baseline and 6-month follow-up in all patients by one
single experienced operator blinded to patients’ treat-
ment. Studies were recorded on super-VHS videotape
(VCR Panasonic AG-MD 835, Osaka, Japan) for off-line
analysis. Echocardiographic parameters were measured
as the consensus of two experienced investigators
masked to patients’ treatment and study order. All
recordings and measurements were obtained according
to current standards of echocardiography practice
[17,19].
Standard 2 D, 2 D guided M-mode and Doppler
measurements
Standard 2 D and M-Mode measurements were
obtained in the parasternal long-axis, short-axis and 4-
chamber apical views and included left atrial diameter,
interventricular septal and posterior wall thickness at
end-diastole (IVSd and PWd respectively), LV end-dia-
stolic and end-systolic diameter (LVDd and LVDs) and
fractional shortening. LVEF was estimated using the
modified Simpson’s method and LV mass using the for-
mula: LV mass = 0.8*(1.04*[(IVSd+PWd+LVDd)
3-
LVDd
3])+0.6 [19]. LV mass was normalized for body
surface area and expressed as LV mass index. LV hyper-
trophy (LVH) was defined as LV mass index >115 and
95 g/m
2 for men and women respectively [19]. Pulsed-
wave Doppler was used to record blood flow velocities
at the mitral inflow area. The sample volume was placed
at the mitral leaflets tips in the apical 4-chamber view.
Figure 1 Flow-chart of the study. CAD, coronary artery disease; HF, heart failure; ECG, electrocardiogram; ECHO, echocardiogram.
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rate of 100 mm/sec, the peak early diastolic and atrial
filling velocity (E and A respectively) were recorded and
the E to A ratio (E/A) was calculated. The E wave decel-
eration time was also measured. Global LV function was
assessed by calculating theT e ii n d e xa sp r e v i o u s l y
described [20].
Tissue Doppler Imaging (TDI)
Mitral annular tissue Doppler velocities were recorded
by pulsed-wave TDI of both septal and lateral walls in
the apical 4-chamber view [17]. Signals were obtained
from 3 end-expiratory cycles, and averages were made
for the systolic and diastolic velocities at a sweep rate of
50 mm/sec. Tissue Doppler systolic (S’) and diastolic
(early, E’; late, A’) velocities were recorded at the septal
and lateral edge of the mitral annulus. From these, aver-
age early diastolic mitral annular velocity was calculated
and the E/E’ ratio was derived. The corresponding tissue
Doppler velocities of the tricuspid annulus (tricuspid S’,
E’ and A’) were also obtained. To assess reproducibility,
15 patients (10 females) were studied on 2 occasions 1
week apart and the primary end-point E’ re-measured
by blinded investigators. A coefficient of variability (SD/
mean of the differences between measurements) of 6.1%
was calculated.
Simple echocardiographic measurements, described in
detail above, were chosen to define LVDD. Evidence of
LVDD was considered if one of the following was pre-
sent: (1) E/A <0.75 or >2, (2) both septal and lateral E’
<8 cm/sec, and (3) septal or lateral E’/A’ ratio <1 [5,17].
Statistical analysis
Results are presented as mean ± SD. Kolmogorov-
Smirnov Z-test was used to determine the normal
distribution of continuous variables: fasting insulin, glu-
cose-to-insulin ratio and HOMA were not normally dis-
tributed. The c
2 test and unpaired Student’s t-test were
used to compare categorical and continuous variables
respectively between the 2 groups at baseline. For not
normally distributed variables the Mann-Whitney test
was used. Within group changes from baseline were
assessed with the paired Student’s t-test or the Wilcox-
on’s test. Repeated Measures Analysis of Variance (RM
ANOVA) was performed to evaluate changes at follow-
up between the 2 groups. Based on pilot data in DM2
patients of both genders, power calculations were per-
formed; 40 patients were required to detect a 15% change
in average E’ with a power of approximately 85% for two-
sided P = 0.05. Pearson and Spearman correlation coeffi-
cients were estimated between baseline E’,a sw e l la s
changes in E’ at 6 months, and all relevant variables in
the 2 groups. A p value of <0.05 was considered signifi-
cant. The SPSS statistical software package (version 15.0
for Windows, SPSS Inc. Chicago, IL, USA) was used.
Results
Eighty-one patients (group A, n = 42 and group B, n =
39) completed the study (assigned treatment and follow-
up investigations) and were included in the analysis
(Figure 1). Two patients in group A discontinued piogli-
tazone; one developed leg edema and one needed insulin
for glycaemic control. Five patients in group B were
withdrawn from the study; 3n e e d e di n s u l i na n d2n o
longer wished to participate. Pioglitazone treatment was
not associated with liver enzyme abnormalities. No
other symptoms or signs of HF or other cardiovascular
adverse events were observed during the 6-month fol-
low-up.
Demographic and clinical characteristics of the 81
patients are shown in Table 1. The two groups consisted
predominantly of women (64 and 72% respectively, P =
NS) and did not differ in age or any other characteristic
(Table 1). All female study participants were postmeno-
pausal and did not receive hormone replacement ther-
apy. Physical and laboratory measurements for both
groups at baseline and 6 months are shown in Table 2.
The two groups did not differ in any parameter at
baseline.
Table 1 Baseline demographic and clinical characteristics
in the 2 groups
Variable Group A
Pioglitazone
(n = 42)
Group B
Other
treatment
(n = 39)
P
value
Age, years (range) 64.3 ± 8.1
(44-77)
64.8 ± 7.5
(48-81)
0.78
Female gender, n (%) 27 (64) 28 (72) 0.49
Hypertensives, n (%) 31 (74) 32 (82) 0.27
Hyperlipidaemics, n (%) 26 (62) 27 (69) 0.64
Ever smokers, n (%) 14 (33) 10 (26) 0.48
Family history of CAD 23 (55) 24 (62) 0.35
Duration of diabetes, years 10.2 ± 6.6 9.0 ± 6.9 0.41
Metformin 31 (74) 26 (67) 0.63
Sulfonylurea 31 (74) 27 (69) 0.81
Metformin & Sulfonylurea 20 (48) 15 (38) 0.50
Antihypertensives, n (%) 27 (64) 27 (69) 0.81
Diuretics, n (%) 6 (14) 8 (21) 0.56
ACE or AT-II inhibitors, n (%) 22 (52) 22 (56) 0.82
b-blockers, n (%) 1 (2) 3 (8) 0.35
Calcium channel blockers, n
(%)
12 (29) 11 (28) 1.00
Statin, n (%) 18 (43) 17 (44) 1.00
Antiplatelets, n (%) 5 (12) 4 (10) 1.00
Mean ± SD unless otherwise stated.
CAD, coronary artery disease; ACE, angiotensin converting enzyme; AT-II,
angiotensin II.
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tion in HbA1C (by 0.57 ± 0.71% and 0.37 ± 0.91% in
groups A and B respectively, p = NS between groups)
and increase in total and LDL cholesterol (p < 0.05 for
both, p = NS between groups) was observed at 6
months. In group A, pioglitazone also induced a signifi-
cant increase in body weight, HDL cholesterol levels
and glucose-to-insulin ratio and a significant reduction
in fasting glucose and insulin, HOMA, and diastolic BP
(p < 0.05 for all). A significant decrease in HDL choles-
t e r o l( p<0 . 0 5 )w a so b s e r v e di ng r o u pB( T a b l e2 ) .
Using RM ANOVA, a significant difference (p < 0.05)
was found between the 2 groups in the treatment-
induced changes in: body weight, diastolic BP, triglycer-
ides, HDL cholesterol, fasting insulin and HOMA.
Changes in other parameters at follow-up did not differ
between the groups.
Echocardiographic observations
By study protocol, all patients enrolled in the study had
preserved LV systolic function and echocardiographic
evidence of LVDD as defined above. No patient had a
restrictive pulsed Doppler pattern (E/A >2). LVH was
present in 29 patients in each group (69% and 74% in
groups A and B respectively, p = NS). No significant dif-
ferences were observed between the 2 groups at baseline
in any conventional or TDI echocardiographic measure-
ments apart from deceleration time that was signifi-
cantly lower in group A (p = 0.04) (Table 3). Baseline E’
correlated inversely with age (r -3.87, p = 0.001) and
presence of hypertension (r -0.359, p = 0.002) in all
patients.
No significant changes were seen in either group in
any echocardiographic measurement at 6 months (p =
NS for all, Table 3). Using RM ANOVA, it was found
that changes at follow-up did not differ significantly
between the 2 groups (p = NS for all). Adjustment for
confounding factors was not needed since no statistical
difference in any baseline characteristics between the
groups (p > 0.27 for all variables) was observed. More
specifically, in both groups E’ velocity increased (by 6.7
± 22.7% and 6.9 ± 30.7% in groups A and B respectively)
and E/E’ ratio decreased at follow-up (by 0.03 ± 16.97%
and 3.18 ± 34.87% respectively), but these changes were
not significant within either group and did not differ
between groups (p = NS for all comparisons). Changes
in E’ at 6 months correlated only with changes in HbA1c
in group A (r -0.484, p = 0.0003) and with age in group
B (r -0.435, p = 0.046). Finally, no significant difference
in the effect of pioglitazone vs the control group B was
found when gender-interaction analysis was performed
or in any high-risk subgroups, i.e. aged >60 years, dia-
betes duration >10 years, hypertensives, patients with
LVH (p > 0.05 for all comparisons, data not shown).
Discussion
Our study indicates that the addition of pioglitazone to
standard oral treatment for 6 months in asymptomatic
DM2 patients with normal systolic function and evi-
dence of LVDD, does not induce any adverse or
Table 2 Physical and laboratory measurements in the 2 groups at baseline and 6-month follow-up
Variable Group A, Pioglitazone
(n = 42)
Group B, Other treatment
(n = 39)
Comparison of changes
between the 2 groups
Baseline Follow-up P value Baseline Follow-up P value P value (RM ANOVA)
Body weight, kg 76.6 ± 12.5 78.8 ± 12.9 0.025 74.2 ± 10.8 74.2 ± 11.7 0.50 0.026
Waist, cm 104.7 ± 11.2 104.0 ± 12.0 0.12 105.6 ± 15.9 104.0 ± 10.2 0.63 0.19
Heart rate, beats/min 73 ± 11 72 ± 11 0.58 73 ± 8 71 ± 10 0.08 0.86
Systolic BP, mmHg 143 ± 15 141 ± 15 0.47 150 ± 17 146 ± 18 0.21 0.62
Diastolic BP, mmHg 78 ± 6 75 ± 7 0.003 78 ± 8 79 ± 9 0.64 0.024
Total cholesterol, mg/dl 214 ± 40 224 ± 45 0.000 212 ± 43 226 ± 44 0.019 0.45
Triglycerides, mg/dl 142 ± 60 134 ± 51 0.31 143 ± 94 160 ± 80 0.050 0.030
HDL cholesterol, mg/dl 53 ± 11 56 ± 12 0.002 56 ± 14 53 ± 12 0.017 0.014
LDL cholesterol, mg/dl 134 ± 33 141 ± 39 0.018 125 ± 44 141 ± 39 0.017 0.22
Fasting glucose, mg/dl 154 ± 31 146 ± 31 0.017 153 ± 33 149 ± 29 0.23 0.37
Fasting insulin, μU/ml 9.9 ± 5.2 7.7 ± 3.3 0.000 9.3 ± 4.8 10.2 ± 5.3 0.42 0.006
HbA1C, % 8.0 ± 0.9 7.5 ± 1.0 0.000 7.9 ± 1.0 7.5 ± 1.3 0.002 0.28
Glucose-to-insulin ratio 19.0 ± 10.3 23.5 ± 13.6 0.000 21.4 ± 15.1 22.1 ± 21.1 0.51 0.08
HOMA 3.9 ± 2.6 2.7 ± 1.2 0.000 3.5 ± 1.8 3.6 ± 1.8 0.38 0.001
Mean ± SD. * p < 0.05 compared to group A
BP, blood pressure; HDL, high density lipoprotein; LDL, low density lipoprotein; HbA1C, glycaeted hemoglobin; HOMA, homeostasis model assessment; RM
ANOVA, repeated measures analysis of variance.
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diastolic or systolic function despite significant meta-
bolic changes. Improvement in glycaemic control and
insulin sensitivity, reduction in BP, increase in body
weight and changes in lipid profile were observed with
pioglitazone treatment.
Pioglitazone and rosiglitazone are the 2 thiazolidine-
diones (TZDs) currently used for the treatment of DM2.
In addition to reducing blood glucose and insulin resis-
tance, several beneficial pleiotropic effects of TZDs have
been reported [6,7,21]. Large clinical studies and meta-
analyses have shown that pioglitazone reduces the risk
of cardiovascular events but its use is associated with
development of non-fatal HF [8,9]. Rosiglitazone has
also been associated with an increased risk of HF and
myocardial infarction [22]. Recent data suggests that
compared with pioglitazone, rosiglitazone administration
was associated with an increased risk of stroke, heart
failure, and all-cause mortality in patients 65 years or
older [23]. The mechanisms underlying the development
of HF after TZDs administration are not fully under-
stood. The combination of fluid retention caused by
TZDs and the high prevalence of LVDD in DM2
patients may explain the increased incidence of HF fol-
lowing TZDs administration [10]. However, TZDs may
also have an effect on cardiac structure and function
Table 3 Echocardiographic measurements in the 2 groups at baseline and 6-month follow-up
Variable Group A, Pioglitazone
(n = 42)
Group B, Other treatment
(n = 39)
Comparison of changes
between the 2 groups
Baseline Follow-up P value Baseline Follow-up P value P value (RM ANOVA)
CONVENTIONAL ECHOCARDIOGRAPHY
Left atrial diameter, mm 39.5 ± 6.1 39.4 ± 5.5 0.84 37.9 ± 5.2 39.1 ± 5.3 0.15 0.22
IVSd, mm 11.4 ± 2.1 11.0 ± 2.0 0.23 11.8 ± 1.8 11.7 ± 2.2 0.79 0.58
PWd, mm 10.7 ± 1.8 10.3 ± 1.8 0.23 11.1 ± 1.6 10.7 ± 1.5 0.14 0.99
LVDd, mm 50.0 ± 5.4 49.6 ± 5.6 0.52 48.6 ± 4.4 47.3 ± 5.7 0.20 0.44
LVDs, mm 29.4 ± 5.8 30.2 ± 4.3 0.31 28.7 ± 4.1 28.8 ± 5.6 0.97 0.49
LV mass index, g/m
2 113.8 ± 27.9 107.8 ± 33.3 0.21 118.1 ± 28.9 110.2 ± 28.2 0.17 0.78
Fractional shortening, (%) 41.4 ± 6.2 40.2 ± 6.1 0.17 41.0 ± 6.5 39.2 ± 8.1 0.14 0.69
Ejection Fraction, (%) 71.4 ± 7.1 69.7 ± 7.2 0.10 71.0 ± 7.7 68.9 ± 9.6 0.13 0.77
E, cm/s 66.1 ± 15.9 66.2 ± 15.5 0.94 62.6 ± 15.4 6.3 ± 14.0 0.26 0.42
A, cm/s 79.6 ± 19.7 81.3 ± 23.7 0.42 80.2 ± 19.6 82.8 ± 14.6 0.23 0.76
E/A ratio 0.87 ± 0.27 0.86 ± 0.23 0.72 0.80 ± 0.20 0.80 ± 0.15 0.88 0.87
Deceleration Time, ms 193 ± 43 194 ± 49 0.88 215 ± 54 * 230 ± 41 0.10 0.16
Tei index 0.35 ± 0.15 0.35 ± 0.22 0.91 0.38 ± 0.18 0.35 ± 0.15 0.37 0.52
TISSUE DOPPLER IMAGING ECHOCARDIOGRAPHY
Septal S’, cm/s 7.9 ± 0.9 8.1 ± 1.1 0.27 7.8 ± 1.2 7.6 ± 1.3 0.59 0.26
Septal E’, cm/s 6.8 ± 1.8 7.0 ± 1.7 0.46 6.7 ± 1.4 7.3 ± 2.1 0.18 0.43
Septal A’, cm/s 10.5 ± 1.6 10.8 ± 1.6 0.29 10.6 ± 2.0 10.3 ± 1.9 0.34 0.15
Septal E’/A’ ratio 0.67 ± 0.22 0.66 ± 0.20 0.87 0.65 ± 0.18 0.71 ± 0.17 0.14 0.23
Lateral S’, cm/s 7.7 ± 1.5 8.1 ± 1.5 0.16 8.0 ± 1.7 8.0 ± 1.6 0.99 0.34
Lateral E’, cm/s 8.1 ± 2.5 8.4 ± 2.5 0.39 8.3 ± 2.0 8.6 ± 3.1 0.45 0.94
Lateral A’, cm/s 11.4 ± 2.4 11.5 ± 2.5 0.84 11.1 ± 2.2 10.7 ± 2.9 0.31 0.40
Lateral E’/A’ ratio 0.75 ± 0.29 0.78 ± 0.38 0.53 0.79 ± 0.27 0.84 ± 0.31 0.39 0.96
Tricuspid S’, cm/s 14.5 ± 2.6 15.4 ± 3.7 0.09 14.1 ± 4.0 14.4 ± 3.3 0.60 0.49
Tricuspid E’, cm/s 12.2 ± 2.9 12.0 ± 3.3 0.63 11.3 ± 3.8 11.9 ± 3.0 0.34 0.29
Tricuspid A’, cm/s 18.3 ± 3.7 18.1 ± 3.9 0.82 17.8 ± 4.5 18.3 ± 4.5 0.42 0.48
Tricuspid E’/A’ ratio 0.69 ± 0.20 0.68 ± 0.24 0.89 0.65 ± 0.18 0.68 ± 0.17 0.36 0.59
E’ (average), cm/s 7.36 ± 1.85 7.66 ± 1.87 0.30 7.55 ± 1.44 7.96 ± 2.31 0.28 0.82
E/E’ 9.14 ± 2.39 9.08 ± 2.71 0.80 8.82 ± 2.61 8.68 ± 2.63 0.73 0.87
Mean ± SD. * p = 0.04 compared to group A.
IVSd/PWd, interventricular/posterior wall end-diastolic thickness; LVDd/LVDs, left ventricular end-diastolic/end-systolic internal diameter; E, early mitral filling
velocity; A, atrial filling velocity; S’,E ’ and A’, systolic, early and late diastolic velocity respectively of the mitral annulus; RM ANOVA, repeated measures analysis of
variance.
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been reported during pioglitazone treatment [24].
Neutral effects on cardiac structure and systolic func-
tion have been reported with pioglitazone in DM2
patients with normal systolic function despite signs of
volume overload and fluid retention [15,25] and in DM2
patients with pre-existing systolic dysfunction despite an
increase in HF hospitalizations [16]. Similar neutral
effects have been observed with rosiglitazone [26,27].
Experimental and some recent clinical studies have
investigated the effect of TZDs on LV diastolic function.
Pioglitazone has been shown to improve LVDD in pre-
diabetic rats [13] or prevent LVDD in type 2 diabetic
rats [14] and several mechanisms such as altered myo-
cardial fatty acid metabolism, improved hyperglycaemia,
hyperlipidaemia, oxidative stress have been implicated.
Effects of pioglitazone on angiogenesis independent of
glucose lowering or PPAR-g activation may also play a
role [28]. In non-diabetic hypertensive patients, pioglita-
zone was shown to improve conventional echocardio-
graphic indices of LV diastolic function (increase in E/A
ratio and deceleration time) [11]. In a small study in
DM2 patients, rosiglitazone caused an increase in mitral
annulus velocity E’ (by 12.7%) indicating improved myo-
cardial diastolic properties, with a concomitant increase
in fractional shortening [2 9 ] .A ni n c r e a s ei ns e p t a lE ’
velocity (by 7.7%), that correlated with a decrease in
plasma type III collagen, was also found following pio-
glitazone treatment in another small study in DM2
patients [18]. In a recent sophisticated MRI/PET study
in men with DM2 and relatively normal cardiac func-
tion, pioglitazone was shown to induce slight changes in
transmitral filling rate and LV diastolic volume at
unchanged filling pressures, compatible with improved
LV compliance [12]; this improvement could not be
explained by any changes in metabolic variables or myo-
cardial substrate metabolism.
In the present study in DM2 patients with LVDD, pio-
glitazone did not appear to have a significant beneficial
or harmful effect on cardiac structure or function,
despite the well known effects of pioglitazone on various
metabolic parameters [6,7,21]. Left atrial and LV dia-
meters and LVEF remained unchanged reflecting prob-
ably absence of significant volume overload, similar to
previous reports [16,18]. LV diastolic properties were
not altered; E’ increased non-significantly and to a simi-
lar extent (by about 7%) in both groups. Myocardial
velocities at the tricuspid annulus remained unchanged,
suggesting also a neutral effect of pioglitazone on the
right ventricle, which has not been previously reported.
Several reasons may explain why the use of pioglita-
zone in the present study was not associated with a ben-
eficial effect on cardiac diastolic properties in contrast to
some recent reports. The population included in the
current study was selected on the basis of evidence of
LVDD that may be attributed to various factors in these
patients; apart from DM2, hypertension and ageing may
also be important contributors. DM2 patients included
in the study had a high incidence of hypertension that is
known to further deteriorate LV diastolic function [30];
baseline E’ in all patients correlated inversely with age
and presence of hypertension similar to previous reports
[30]. Whatever the components of LVDD in these
patients, its presence suggests some myocardial involve-
ment that may have limited the potential beneficial
effects of pioglitazone on diastolic function. Increased
myocardial fibrosis has been associated with LVDD and
such structural changes are considered to be less amen-
able to treatment [31]. Furthermore, the benefit asso-
ciated with the use of pioglitazone may be too small to
be detected even with the use of TDI methodology that
is considered superior to conventional echocardiography
for the assessment of LV function [5,17,32]. In any case,
great changes in myocardial diastolic properties that
would be easily detected by echocardiography and
would probably lead to improved clinical outcome have
not been observed with 6-month pioglitazone treatment.
In the present study, the increase in E’ velocity with pio-
glitazone was associated with the improvement in gly-
caemic control. It may be possible that a higher dose of
pioglitazone leading to better glycaemic control may
have been necessary to induce significant changes. How-
ever, the extent of metabolic control amelioration has
not associated with the improvement in LV diastolic
function in a recent randomized trial comparing insulin
to metformin/sulfonylureas [33].
Study limitations
Although this was a single-center study, the study popu-
lation provided adequate power to detect modest
changes in echocardiographic indices of LV diastolic
function that were estimated based on previous studies
[12,18,29] and the reproducibility of our methodology.
This was a randomized, open-label study, but echocar-
diographic recordings and measurements were per-
formed by operators blinded to patients’ treatment. Our
population consisted mainly of postmenopausal females
and hence the reported results may not be applicable to
the general population. However, gender-interaction
analysis excluded a possible gender effect in our study.
Other medications received by study participants (e.g.
angiotensin converting enzyme or angiotensin II inhibi-
tors, calcium channel blockers) may have affected LV
diastolic function, potentially attenuating the effect of
pioglitazone; however, no changes were allowed during
the study. A combination of simple and easy-to-acquire
criteria was used for the detection of LVDD; their selec-
tion was based on previous publications since
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only recently published [34]. Although these criteria are
largely included in recent recommendations on LV dia-
stolic function evaluation [ 3 4 ] ,i tc a n n o tb ee x c l u d e d
that LVDD may be over-diagnosed in a small number of
patients. More sophisticated measures such as the aver-
age diastolic velocities from all points in the mitral
annulus or the left atrial volume could be used in future
research to reveal more subtle changes in LV diastolic
function. Only one patient developed leg edema, without
any other symptoms or signs of HF, during the study in
the pioglitazone group and the patient discontinued pio-
glitazone on his own long before any follow-up echocar-
diography could be performed. Finally, coronary artery
disease was not vigorously excluded with angiography or
non-invasive assessment of inducible ischemia; the
potential presence of coronary artery disease may have
affected the effect of pioglitazone on diastolic function.
Conclusions
In asymptomatic DM2 patients with evidence of LVDD
and preserved systolic function, 6-month treatment with
pioglitazone has no favorable or harmful effect on echo-
cardiographic indices of cardiac structure, systolic or
diastolic function despite favorable effects on glycaemic
control, insulin resistance, lipid profile and blood pres-
sure. Although the use of TZDs has been associated
with induction of HF in some DM2 patients, pioglita-
zone did not appear to have a harmful effect on intrinsic
diastolic properties of the myocardium in DM2 patients
with pre-existing LVDD. Larger studies with more sensi-
tive methods are needed in order to reveal potential
beneficial effects of pioglitazone on myocardial diastolic
properties.
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